<DOC>
	<DOCNO>NCT00677248</DOCNO>
	<brief_summary>Eprotirome ( KB2115 ) liver selective thyroid hormone induce hyperthyroidism liver , euthyroid state preserve extrahepatic tissue . Eprotirome clinical trial demonstrate pronounced reduction several independent risk factor development atherosclerotic cardiovascular disease . The purpose study assess efficacy safety KB2115 add therapy ezetimibe follow 10 week exposure compare placebo . The aim study ass efficacy ( LDL-cholesterol lower effect ) safety KB2115 define clinically relevant dose dose range future study .</brief_summary>
	<brief_title>LDL-Cholesterol Lowering Effect KB2115 Add Ezetimibe</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<criteria>Males female age 18 75 year Patient primary hypercholesterolemia LDLcholesterol &gt; 3.0 mmol/L At randomization , diet instruct investigator last 4 week prior randomization willingness follow instruction throughout study History somatic psychiatric disease/condition , may interfere objective study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>Eprotirome</keyword>
	<keyword>KB2115</keyword>
	<keyword>dyslipidemia</keyword>
	<keyword>hypercholesterolemia</keyword>
	<keyword>hypertriglyceridemia</keyword>
</DOC>